Citations

Showing 10 of 108162 citations.

Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement on Perioperative Smoking Cessation
An, Dong Ai , Tønnesen, Hanne , Raveendran, Raviraj, Abdullah, Hairil Rizal , Pfeifer, Kurt , Maa, John, Finegan, Barry A. , Li, Emily, Webb, Ashley , Edwards, Angela F., Preston, Paul, Bentov, Nathalie , Richman, Deborah C. , Wong, Jean , Urman, Richard D , Warner, David O. , Chung, Frances

Mayo Clinic

Anesthesia & Analgesia | November 25, 2019 | Volume: 131 | Issue: 3 | Pages: 955-968

10.1213/ane.0000000000004508 | PMID 31764157 Get It

Smokers are at increased risk for surgical complications. Despite the known benefits of smoking cessation, many perioperative health care providers do not routinely provide smoking cessation interventions. The variation in delivery of perioperative smoking cessation interventions may be due to limited high-level evidence for whether smoking cessation interventions used in the general population are effective and feasible in the surgical population, as well as the challenges and barriers to implementation of interventions. Yet smoking is a potentially modifiable risk factor for improving short- and long-term patient outcomes. The purpose of the Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement on Perioperative Smoking Cessation is to present recommendations based on current scientific evidence in surgical patients. These statements address questions regarding the timing and intensity of interventions, roles of perioperative health care providers, and behavioral and pharmacological interventions. Barriers and strategies to overcome challenges surrounding implementation of interventions and future areas of research are identified. These statements are based on the current state of knowledge and its interpretation by a multidisciplinary group of experts at the time of publication.
Atrial Fibrillation: Should Lifelong Athletes Be Worried?
Drum, Scott N. , Donath, Lars , Dehlin, Chris, Kashou, Anthony H. , Noseworthy, Peter A. , Zacher, Jonas

Mayo Clinic

Strength & Conditioning Journal | November 25, 2019 | Volume: 42 | Issue: 2 | Pages: 122-130

10.1519/ssc.0000000000000515 Get It

ABSTRACT Atrial fibrillation (AF) in lifetime athletes (e.g., ≥5 years of participation) is a growing concern but remains enigmatic. Intriguingly, a direct relationship between lifetime training hours and risk of developing AF exists. Professionals in exercise and sport science are at the forefront to help recognize symptoms and direct the athlete to appropriate medical clinicians for expedient care. Although AF in athletes is usually not accompanied by structural heart disease or stroke risk factors (i.e., termed lone AF), it may, nonetheless, pose health risks. In this study, we review various types of AF, proposed mechanisms, and treatment strategies for athletes with AF.
Training, testing and remediating: the importance of simulation for surgical trainees
Chandra, Abhishek , Rajesh, Aashish , Backstrom, Courtney, Farley, David R. , Chandra, Abhishek

Mayo Clinic

ANZ Journal of Surgery | November 25, 2019 | Volume: 89 | Issue: 11 | Pages: 1364-1365

10.1111/ans.15274 | PMID 31760701 Get It

Ultra-low-dose (boom-boom) radiotherapy for choroidal lymphoma in three consecutive cases
Yang, Xiaolu , Lim, Li‐Anne , Shields, Jerry A., Shields, Carol L. , Shields, Carol L , Dalvin, Lauren A. , Mashayekhi, Arman

Mayo Clinic

European Journal of Ophthalmology | November 25, 2019 | Volume: 31 | Issue: 2 | Pages: NP91-NP96

10.1177/1120672119888985 | PMID 31760781 Get It

Purpose: To describe the outcome of ultra-low-dose (boom-boom) radiotherapy for choroidal lymphoma. Methods: Retrospective series of three consecutive patients with biopsy-proven choroidal lymphoma treated with ultra-low-dose radiotherapy. Results: The three patients (two male, one female) of mean age 70 years (range, 64–74 years) demonstrated presenting visual acuity in the affected eye between 20/40 and 20/50. The choroidal lymphoma was unilateral in all cases and presented with multifocal yellow patchy choroidal infiltration, located in all four quadrants and measuring mean 2.9 mm (range, 1.9–4.0 mm) in thickness by ultrasonography. Anterior epibulbar extension of 5 mm diameter was noted in one case. By enhanced depth imaging optical coherence tomography, the choroidal infiltration demonstrated classic undulating appearance (n = 3), with subretinal fluid (n = 2) and intraretinal edema (n = 1). There was no systemic lymphoma in any case. Biopsy was performed in all three cases and was diagnostic (n = 1) or suggestive (n = 2) of B-cell lymphoma. Management involved ultra-low-dose radiotherapy (4 Gy delivered in two fractions, “boom-boom”). On follow-up (mean = 14 months, range = 6–24 months), complete tumor regression on ophthalmoscopy was documented in all three cases, with enhanced depth imaging optical coherence tomography and ultrasonography demonstrating evidence of lymphoma resolution and visual acuity improvement to 20/25–20/40. There were no radiation complications. Conclusion: In this small case series, ultra-low-dose (boom-boom) radiotherapy was effective for choroidal lymphoma with favorable response and minimal side effects.
Hybrid 3D analytical linear energy transfer calculation algorithm based on precalculated data from Monte Carlo simulations
Ding, Xiaoning, Younkin, James E. , Shen, Jiajian , Patel, Samir H. , Bues, Martin , Schild, Steven E. , Shen, Jiajian , Deng, Wei, Liu, Wei

Mayo Clinic

Medical Physics | November 23, 2019 | Volume: 47 | Issue: 2 | Pages: 745-752

10.1002/mp.13934 | PMID 31758864 Get It

PurposeThe dose‐averaged linear energy transfer (LETd) for intensity‐modulated proton therapy (IMPT) calculated by one‐dimensional (1D) analytical models deviates from more accurate but time‐consuming Monte Carlo (MC) simulations. We developed a fast hybrid three‐dimensional (3D) analytical LETd calculation that is more accurate than 1D analytical model.MethodsWe used the Geant4 MC code to generate 3D LETd distributions of monoenergetic proton beams in water for all energies and used a customized error function to fit the LETd lateral profiles at various depths to the MC simulation. The 3D LETd calculation kernel was a lookup table of these fitted coefficients, and LETd was determined directly from spot energies and voxel coordinates during analytical dose calculations. We validated our new method by comparing the calculated LETd distributions to MC results using 3D Gamma index analysis with 3%/2 mm criteria in 12 patient geometries. The significance of the improvement in Gamma index analysis passing rates over the 1D analytical model was determined using the Wilcoxon rank‐sum test.ResultsThe passing rate of 3D Gamma analysis comparing LETd distributions from the hybrid 3D method and the 1D method to MC simulations was significantly improved from 94.0% ± 2.5% to 98.0% ± 1.0% (P = 0.0003). The typical time to calculate dose and LETd simultaneously using an Intel Xeon E5‐2680 2.50 GHz workstation was approximately 2.5 min.ConclusionsOur new method significantly improved the LETd calculation accuracy compared to the 1D method while maintaining significantly shorter calculation time even comparing with the GPU‐based fast MC code.
New methods for objective angiogenesis evaluation of rat nerves using microcomputed tomography scanning and conventional photography
Saffari, Tiam M. , Mathot, Femke , Shin, Alexander Y. , Shin, Alexander Y , Bishop, Allen T.

Mayo Clinic

Microsurgery | November 23, 2019 | Volume: 40 | Issue: 3 | Pages: 370-376

10.1002/micr.30537 | PMID 31758730 Get It

AbstractIntroductionNerve regeneration involves multiple processes, which enhance blood supply that can be promoted by growth factors. Currently, tools are lacking to visualize the vascularization patterns in transplanted nerves in vivo. The purpose of this study was to describe three‐dimensional visualization of the vascular system in the rat sciatic nerve and to quantify angiogenesis of nerve reconstruction.Materials and MethodsIn 12 Lewis rats (weighing 250–300 g), 10 mm sciatic nerve gaps were repaired with ipsilateral reversed autologous nerve grafts. At 12 and 16 weeks of sacrifice, Microfil® contrast compound was injected in the aorta. Nerve autografts (N = 12) and contralateral untreated nerves (N = 12) were harvested and cleared while preserving the vasculature. The amount of vascularization was measured by quantifying the vascular surface area using conventional photography (two‐dimensional) and the vascular volume was calculated with microcomputed tomography (three‐dimensional). For each measurement, a vessel/nerve area ratio was calculated and expressed in percentages (vessel%).ResultsThe vascular volume measured 3.53 ± 0.43% in autografts and 4.83 ± 0.45% vessels in controls at 12 weeks and 4.95 ± 0.44% and 6.19 ± 0.29% vessels at 16 weeks, respectively. The vascular surface area measured 25.04 ± 2.77% in autografts and 26.87 ± 2.13% vessels in controls at 12 weeks, and 28.11 ± 3.47% and 33.71 ± 2.60% vessels at 16 weeks, respectively. The correlation between both methods was statistically significant (p = .049).ConclusionsBoth methods are considered to successfully reflect the degree of vascularization. Application of this technique could be used to visualize and objectively quantify angiogenesis of the transplanted nerve graft. Moreover, this simple method is easily reproducible and could be extrapolated to any other desired target organ ex vivo in small animals to investigate the vascular network.
What is the effect of a decision aid in potentially vulnerable parents? Insights from the head CT choice randomized trial
Skains, Rachel M. , Kuppermann, Nathan , Homme, James L. , Kharbanda, Anupam B. , Tzimenatos, Leah, Louie, Jeffrey P. , Cohen, Daniel M. , Westphal, Jessica J., Shah, Nilay D. , Inselman, Jonathan , Ferrara, Michael J. , Montori, Victor M , Hess, Erik P. , Skains, Rachel M , Nigrovic, Lise E. , Herrin, Jeph , Montori, Víctor M.

Mayo Clinic

Health Expectations | November 23, 2019 | Volume: 23 | Issue: 1 | Pages: 63-74

10.1111/hex.12965 | PMID 31758633 Get It

AbstractObjectiveTo test the hypotheses that use of the Head CT Choice decision aid would be similarly effective in all parent/patient dyads but parents with high (vs low) numeracy experience a greater increase in knowledge while those with low (vs high) health literacy experience a greater increase in trust.MethodsThis was a secondary analysis of a cluster randomized trial conducted at seven sites. One hundred seventy‐two clinicians caring for 971 children at intermediate risk for clinically important traumatic brain injuries were randomized to shared decision making facilitated by the DA (n = 493) or to usual care (n = 478). We assessed for subgroup effects based on patient and parent characteristics, including socioeconomic status (health literacy, numeracy and income). We tested for interactions using regression models with indicators for arm assignment and study site.ResultsThe decision aid did not increase knowledge more in parents with high numeracy (P for interaction [Pint] = 0.14) or physician trust more in parents with low health literacy (Pint = 0.34). The decision aid decreased decisional conflict more in non‐white parents (decisional conflict scale, −8.14, 95% CI: −12.33 to −3.95; Pint = 0.05) and increased physician trust more in socioeconomically disadvantaged parents (trust in physician scale, OR: 8.59, 95% CI: 2.35‐14.83; Pint = 0.04).ConclusionsUse of the Head CT Choice decision aid resulted in less decisional conflict in non‐white parents and greater physician trust in socioeconomically disadvantaged parents. Decision aids may be particularly effective in potentially vulnerable parents.
Multi‐site reproducibility of a human immunophenotyping assay in whole blood and peripheral blood mononuclear cells preparations using CyTOF technology coupled with Maxpar Pathsetter, an automated data analysis system
Bagwell, Charles Bruce, Hunsberger, Benjamin C., Hill, Beth L., Herbert, Donald J., Bray, Christopher C., Strausbauch, Michael, KELLY, GREGORY J. C., Gomez‐Cabrero, Azucena, Behbehani, Gregory K. , Chang, Hsiaochi , Lyberger, Justin , Montgomery, Ruth R. , Zhao, Yujiao , Inokuma, Margaret, Goldberger, Ofir, Stelzer, Greg , Pavelko, Kevin, Bray, Christopher, Selvanantham, Thirumahal , Li, Stephen , Villasboas, José C. , Pavelko, Kevin D. , Rahman, Adeeb H , Asgharzadeh, Shahab

Mayo Clinic

Cytometry Part B: Clinical Cytometry | November 23, 2019 | Volume: 98 | Issue: 2 | Pages: 146-160

10.1002/cyto.b.21858 | PMID 31758746 Get It

Abstract High‐dimensional mass cytometry data potentially enable a comprehensive characterization of immune cells. In order to positively affect clinical trials and translational clinical research, this advanced technology needs to demonstrate a high reproducibility of results across multiple sites for both peripheral blood mononuclear cells (PBMC) and whole blood preparations. A dry 30‐marker broad immunophenotyping panel and customized automated analysis software were recently engineered and are commercially available as the Fluidigm® Maxpar® Direct™ Immune Profiling Assay™. In this study, seven sites received whole blood and six sites received PBMC samples from single donors over a 2‐week interval. Each site labeled replicate samples and acquired data on Helios™ instruments using an assay‐specific acquisition template. All acquired sample files were then automatically analyzed by Maxpar Pathsetter™ software. A cleanup step eliminated debris, dead cells, aggregates, and normalization beads. The second step automatically enumerated 37 immune cell populations and performed label intensity assessments on all 30 markers. The inter‐site reproducibility of the 37 quantified cell populations had consistent population frequencies, with an average %CV of 14.4% for whole blood and 17.7% for PBMC. The dry reagent coupled with automated data analysis is not only convenient but also provides a high degree of reproducibility within and among multiple test sites resulting in a comprehensive yet practical solution for deep immune phenotyping.
Venous thromboembolism chemoprophylaxis in mastectomy patients: A 5‐year follow‐up study
Vu, T. N. Diem , Melik, Razan El, Nehring, Sharon, Bergquist, Whitney J., Day, Courtney N. , Jakub, James W. , Melik, Razan M. El , Bergquist, Whitney, Hoskin, Tanya, Day, Courtney, Jakub, James W , El Melik, Razan M , Hoskin, Tanya L.

Mayo Clinic

Journal of Surgical Oncology | November 23, 2019 | Volume: 121 | Issue: 2 | Pages: 193-199

10.1002/jso.25771 | PMID 31758708 Get It

AbstractBackgroundVenous thromboembolism (VTE) chemoprophylaxis in breast surgery remains controversial. In 2012, we instituted a practice change of routine chemoprophylaxis for patients with invasive cancer undergoing mastectomy. Herein, we report the effects of this on rates of VTE and hematoma.MethodsOur 30‐day rates of VTE and hematoma requiring reoperation among patients with mastectomy since the practice change were retrospectively collected from National Surgical Quality Improvement Program (NSQIP). The subsequent 5‐year data (2012‐2017) was compared with historic NSQIP data (2006‐2010). We utilized information from our 30‐day follow‐up databank to assess patients not sampled by NSQIP.ResultsAfter the practice change, the heparin prophylaxis rate rose from 19.5% to 95.6% (P < .001) and the VTE rate fell from 0.8% to 0% (P = .30). There was no significant change in reoperative hematoma rate (P = .39). The majority of the current NSQIP patient population (93.1%) had a Caprini score of 5 or greater. Among 663 patients obtained from 30‐day postoperative follow‐up, there were 2 VTE (0.3%) and 7 (1.1%) reoperations for hematoma.ConclusionsThe practice change resulted in an increase of VTE chemoprophylaxis without significant change in hematoma incidence. Although not statistically significant, VTE incidence decreased. This supports the use of standardized VTE chemoprophylaxis in this population and warrants further study.
Association between patient age and the risk of mortality following local recurrence of a sacral chordoma
Houdek, Matthew T. , Schwab, Joseph H. , Yaszemski, Michael J. , Griffin, Anthony M. , Healey, John H. , Hornicek, Francis J. , Boland, Patrick J. , Sim, Franklin H. , Rose, Peter S. , Boland, Patrick J , Houdek, Matthew T , Hevesi, Mario , Ferguson, Peter C. , Wunder, Jay S.

Mayo Clinic

Journal of Surgical Oncology | November 23, 2019 | Volume: 121 | Issue: 2 | Pages: 267-271

10.1002/jso.25774 | PMID 31758570 Get It

AbstractBackgroundLocal recurrence (LR) of sacral chordoma is a difficult problem and the mortality risk associated with LR remains poorly described. The purpose of this study was to evaluate the risk of mortality in patients with LR and determine if patient age is associated with mortality.MethodsA total of 218 patients (144 male, 69 female; mean age 59 ± 15 years) with sacrococcygeal chordomas were reviewed. Cumulative incidence functions and competing risks for death due to disease and nondisease mortality were employed to analyze mortality trends following LR.ResultsThe 10‐year overall survival (OS) was 55%. Patients with LR had 44% 10‐year OS, similar to patients without (59%; P = .38). The 10‐year OS between those less than 55 compared with ≥55 years were similar (69% vs 48%; P = .52). The 10‐year death due to disease was worse in patients with LR compared with those without (44% vs 84%; P < .001). In patients without LR, patients ≥55 years were 1.6‐fold more likely to experience death due to other causes.ConclusionsPatients with an LR are more likely to die due to disease. Advanced patient age was associated with higher all‐cause mortality following resection of sacral chordoma. LR of chordoma was associated with increased disease‐specific mortality, regardless of age.